Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs KRYS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KRYS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

KRYS Overall Winner 6-Pillar Tally: IONS 2 – 4 KRYS Matrix Metrics: IONS 2 – 8 KRYS

As of Nov 16, 2026, Krystal Biotech, Inc. (KRYS) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas KRYS carries 51.1/100 (HOLD) at $297.67 (33.1x Forward P/E, 48.4% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. KRYS 51.1/100 HOLD), KRYS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (48.4% vs. -58.8% operating margin) and revenue trajectory (+30.2% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile KRYS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs KRYS
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
KRYS NASDAQ Head-to-Head Winner
Krystal Biotech, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$297.67
-2.48% 1D
Market Cap $9.1B
TTM Revenue $470M
Forward P/E 33.1x
Beta / 30D Vol 0.69β · 47% Vol
Unified Composite Score
51.1 / 100 HOLD
Tech 59.0 Fund 57.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.1%), weak momentum, RSI 39
RSI-14: 39.1 · SMA20: $311.58 · SMA50: $325.55

6-Pillar Scorecard Institutional Category Breakdown (IONS 2 – 4 KRYS)

Columns: Metric · IONS · KRYS
1. Valuation Multiples KRYS
Forward P/E 90.9x 33.1x
Trailing P/E 90.9x 41.5x
PEG Ratio N/M N/M
EV / Revenue 6.2x 18.3x
2. Growth & Scale IONS
Revenue Growth (YoY) +54.9% +30.2%
Earnings Growth (YoY) -43.7% -22.9%
TTM Revenue (USD) $960M $470M
Market Cap $4.7B $9.1B
3. Profitability & Quality KRYS
Gross Margin 3.0% 94.3%
Operating Margin -58.8% 48.4%
Net Profit Margin -56.9% 47.9%
Return on Equity (ROE) -108.0% 17.5%
4. Balance Sheet & Cash Flow KRYS
Cash Generation (TTM) -$623M $310M
Cash Flow Margin -64.9% 66.0%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $454M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KRYS
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 59.9% (17th %ile) 40.3% (4th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.14x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 45.9% of Rev ($216M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (2) vs KRYS (8)
Institutional Metric IONS KRYS Criterion Row Edge
Market Capitalization
Scale
$4.7B $9.1B Larger Scale KRYS
Trailing P/E Ratio
Valuation
90.9x 41.5x Lower Multiple KRYS
Forward P/E Ratio
Valuation
90.9x 33.1x Lower Multiple KRYS
Revenue Growth (YoY)
Growth
+54.9% +30.2% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% 48.4% Higher Margin KRYS
Net Profit Margin
Profitability
-56.9% 47.9% Higher Margin KRYS
Return on Equity (ROE)
Capital Efficiency
-108.0% 17.5% Higher ROE KRYS
52-Week Range Position
Momentum
2% ($27–$87) 54% ($198–$383) Stronger Trend KRYS
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.69β · 47% Vol Lower Realized Risk KRYS
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 51.1 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $470M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 94.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 18.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) $310M ($454M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KRYS +27.51 pp
IONS: -33.48% · KRYS: -5.97%
3M Horizon KRYS +41.53 pp
IONS: -52.09% · KRYS: -10.56%
6M Horizon KRYS +62.64 pp
IONS: -60.61% · KRYS: +2.03%
1Y Horizon KRYS +107.04 pp
IONS: -59.1% · KRYS: +47.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue KRYS Revenue IONS Op. Margin KRYS Op. Margin Margin Leader
FY2018 $600M N/A -10.2% N/A IONS
FY2019 $1.12B N/A 32.6% N/A IONS
FY2020 $730M N/A -23.6% N/A IONS
FY2021 $810M N/A -3.7% N/A IONS
FY2022 $590M N/A -69.8% N/A IONS
FY2023 $790M $50M -44.9% -216.2% IONS
FY2024 $710M $290M -67.4% 22.6% KRYS
FY2025 $940M $390M -40.4% 41.5% KRYS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KRYS CONSOLIDATION
98d in phase · OBV ACCUMULATION
Current IV 40.3%
IV Percentile 4th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KRYS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
KRYS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $9.1B market capitalization and 48.4% operating margin.
OpEx & R&D Reinvestment 45.9% of Rev ($216M)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs KRYS Key Questions & Quantitative Answers

As of Nov 16, 2026, Krystal Biotech, Inc. (KRYS) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas KRYS carries 51.1/100 (HOLD) at $297.67 (33.1x Forward P/E, 48.4% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. KRYS 51.1/100 HOLD), KRYS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (48.4% vs. -58.8% operating margin) and revenue trajectory (+30.2% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile KRYS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with KRYS at +30.2% YoY revenue growth and -22.9% YoY earnings growth on $470M TTM revenue (94.3% gross margin, 48.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while KRYS shifted +680.0%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 45.9% of Rev ($216M) (0 disclosures) for KRYS.

KRYS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas KRYS trades at 33.1x Forward P/E, 41.5x Trailing P/E, N/M PEG, and 18.3x EV/Revenue (66.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus KRYS (17.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, KRYS carries 40.3% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.69β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.